Rare & Genetic DiseasesDec 01, 2020|2 min readBy DDNews StaffNegative news for Ovid Therapeutics’ OV101Phase 3 NEPTUNE trial of OV101 for treatment of Angelman syndrome failed to meet primary endpoint